Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современные рекомендации по лечению ревматоидного артрита
Современные рекомендации по лечению ревматоидного артрита
Балабанова Р.М. Современные рекомендации по лечению ревматоидного артрита. Consilium Medicum. 2014; 16 (9): 119–122.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Smolen JS, Landewe R, Breedveld FC et al. EULAR recomendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs; 2013 update. Ann Rheum Dis 2013. DOI: 10.1136/annrheumdis-2013-204573
2. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Научно-практическая ревматология. 2013; 6 (51): 609–22. DOI:http:// dx.doi.org/ 10.14412/1995-4484-2013-609-22
3. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 69 (2): 2569–81. DOI:10.1002/art/27584
4. Balsa A, De Miguel E, Castillo C et al. Superiority of SDAI jver DAS 28 in assessment of remission in rheumatoid arthritis hatients using power Doppler ultrasonography as a gold standart. Rheumatology (Oxford) 2010; 49 (4): 683–90. DOI:10.1093/ rheumatology/ kep442.Epub 2010 Jan 4
5. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63 (3): 573–86. DOI: 10.1002/art.30129
6. Насонов Е.Л. Лечение ревматоидного артрита 2012: место метотрексата. Научно-практическая ревматология. 2012; 51 (2): 1–24.
7. Van Dongen H, Van Aken J, Lard L et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56 (5): 1424–32. DOI: http://dx.doi.org/10.1002/art.22525
8. Wewers-de Boer K, Visser K, Heimans L et al. Remission induction therapy with methotrexate and prednisolone in patients with early rheumatoid and undifferentiated arthritis. (the IMPROVED study). Ann Rheum Dis 2012; 71 (9): 1472–7. DOI:10.1136/annrheumdos-2011-200736
9. Braun J, Kastner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58 (1): 73–81. DOI:10.1002/ art.23144
10. Bykerk V, Rowe D, Thorne C et al. Increased remission rates in patients receiving early optimal doses of parenteral methotrexat vs other therapeutic strategies from a nationwade early rheumatoid cohort. Ann Rheum Dis 2010; 69 (Suppl. 3): 65.
11. Wasco MCM, Dasgupta A, Hubert H et al. Propensity-adjusted association of methotrexat with overall survival in rheumatoid arthritis. Arthritis Rheum 2012; 10: 3772.
12. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014; 6 (51): 609–22. DOI:http://dx.doi.org/10.14412/1995-4484-2014-8-26
13. O´Dell JR, Mikuls TR, Taylor TH et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369 (4): 307–18. DOI: 10.1056/NEJMoa1303006.Epub 2013 Jun 11
14. Sokka T, Pincus N. Rheumatoid arthritis: strategy more important than agent. Lancet 2009; 374 (9688): 430–2. DOI:10.1016/S0140-6736(09)61432-X
15. Kawalec P, Mikrut A, Wisniewska N et al. The effectiveness of tofacitinib, a novel Janus kinase inhibitor. In the treatment of rheumatoid arthritis: a systemic review and metha-analiysis. Clin Rheumatol 2013; 32 (10): 1414–24. DOI:10.1007/s10067-013-2329-9
16. Klarenbeek NB, Van der Kooij SM, Guler-Yuksel M et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011; 70 (2): 315–9. DOI:10.1136/ ard.2010.136556. Epub 2010 Nov 10
17. Weslake SL, Colebatch AN, Baird J et al. The effect of methotrexate jn cardiovascular disease in patients with rheumatoid arthritis: a systemic literature review. Rheumatology (Oxford) 2010; 49 (2): 295–307. D OI:10.1093/rheumatology/kep366.Epub 2009 Nov 27
18. Sandrini G, Proietti Cecchini A, Alfonsi E et al. The effectivenes of nimesulide in hain. A neurophysiological study in humans. Drugs of Today 2001; 37 (Suppl. B): 21–9.
19. Rabasseda X. Safety profile of nimesulide: ten years of clinical experience. Drugs of Today 1997; 33 (Suppl. 1): 41–50.
2. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Научно-практическая ревматология. 2013; 6 (51): 609–22. DOI:http:// dx.doi.org/ 10.14412/1995-4484-2013-609-22
3. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 69 (2): 2569–81. DOI:10.1002/art/27584
4. Balsa A, De Miguel E, Castillo C et al. Superiority of SDAI jver DAS 28 in assessment of remission in rheumatoid arthritis hatients using power Doppler ultrasonography as a gold standart. Rheumatology (Oxford) 2010; 49 (4): 683–90. DOI:10.1093/ rheumatology/ kep442.Epub 2010 Jan 4
5. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63 (3): 573–86. DOI: 10.1002/art.30129
6. Насонов Е.Л. Лечение ревматоидного артрита 2012: место метотрексата. Научно-практическая ревматология. 2012; 51 (2): 1–24.
7. Van Dongen H, Van Aken J, Lard L et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 56 (5): 1424–32. DOI: http://dx.doi.org/10.1002/art.22525
8. Wewers-de Boer K, Visser K, Heimans L et al. Remission induction therapy with methotrexate and prednisolone in patients with early rheumatoid and undifferentiated arthritis. (the IMPROVED study). Ann Rheum Dis 2012; 71 (9): 1472–7. DOI:10.1136/annrheumdos-2011-200736
9. Braun J, Kastner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58 (1): 73–81. DOI:10.1002/ art.23144
10. Bykerk V, Rowe D, Thorne C et al. Increased remission rates in patients receiving early optimal doses of parenteral methotrexat vs other therapeutic strategies from a nationwade early rheumatoid cohort. Ann Rheum Dis 2010; 69 (Suppl. 3): 65.
11. Wasco MCM, Dasgupta A, Hubert H et al. Propensity-adjusted association of methotrexat with overall survival in rheumatoid arthritis. Arthritis Rheum 2012; 10: 3772.
12. Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014; 6 (51): 609–22. DOI:http://dx.doi.org/10.14412/1995-4484-2014-8-26
13. O´Dell JR, Mikuls TR, Taylor TH et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369 (4): 307–18. DOI: 10.1056/NEJMoa1303006.Epub 2013 Jun 11
14. Sokka T, Pincus N. Rheumatoid arthritis: strategy more important than agent. Lancet 2009; 374 (9688): 430–2. DOI:10.1016/S0140-6736(09)61432-X
15. Kawalec P, Mikrut A, Wisniewska N et al. The effectiveness of tofacitinib, a novel Janus kinase inhibitor. In the treatment of rheumatoid arthritis: a systemic review and metha-analiysis. Clin Rheumatol 2013; 32 (10): 1414–24. DOI:10.1007/s10067-013-2329-9
16. Klarenbeek NB, Van der Kooij SM, Guler-Yuksel M et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011; 70 (2): 315–9. DOI:10.1136/ ard.2010.136556. Epub 2010 Nov 10
17. Weslake SL, Colebatch AN, Baird J et al. The effect of methotrexate jn cardiovascular disease in patients with rheumatoid arthritis: a systemic literature review. Rheumatology (Oxford) 2010; 49 (2): 295–307. D OI:10.1093/rheumatology/kep366.Epub 2009 Nov 27
18. Sandrini G, Proietti Cecchini A, Alfonsi E et al. The effectivenes of nimesulide in hain. A neurophysiological study in humans. Drugs of Today 2001; 37 (Suppl. B): 21–9.
19. Rabasseda X. Safety profile of nimesulide: ten years of clinical experience. Drugs of Today 1997; 33 (Suppl. 1): 41–50.
Авторы
Р.М.Балабанова
ФГБУ НИИ ревматологии им. В.А.Насоновой РАН, Москва
ФГБУ НИИ ревматологии им. В.А.Насоновой РАН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.